Rapid response on facial psoriasis to bimekizumab: case series.
Nicoletta BernardiniAnnunziata DattolaGiacomo CaldarolaDiego OrsiniChiara AssorgiAlessandra D'AmoreGiulia MarettiAntonio Giovanni RichettaErsilia TolinoNevena SkrozaConcetta PotenzaPublished in: Drugs in context (2024)
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.
Keyphrases
- phase iii
- end stage renal disease
- atopic dermatitis
- clinical trial
- soft tissue
- chronic kidney disease
- ejection fraction
- newly diagnosed
- open label
- rheumatoid arthritis
- coronary artery disease
- peritoneal dialysis
- prognostic factors
- oxidative stress
- loop mediated isothermal amplification
- double blind
- disease activity
- ankylosing spondylitis
- depressive symptoms
- placebo controlled